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Abstract
Cannabinoid type-1 (CB1) receptor antagonists were
among the most promising drug targets in the last decade.
They have been explored and found to be effective as
therapeutic agents for obesity and related cardiometabolic
problems, including e.g. dyslipidaemias, diabetes, and
metabolic syndrome. However, the use of rimonabant, the
first marketed CB1 receptor antagonist, has been sus-
pended due to its anxiogenic and depressogenic side
effects, which were present in about 20–30% of the
patients, i.e. a 2.5–3-fold increase compared to placebo.
Since some other anti-obesity drugs like dexfenfluramine
or sibutramine were also suspended, the unmet need for
drugs that reduce body weight became enormous. One
approach that emerged was the development of peripheral
CB1 receptor antagonists that poorly cross the blood brain
barrier, the second, the development of neutral antagonists
instead of inverse agonists, and the third, the selection of
the patient population with reduced risk for psychiatric
side effects. An analysis regarding peripheral and central
mechanisms involved in the effects of CB1 receptor
antagonists strongly suggest that central mechanisms are
more or less involved in most cardiometabolic therapeutic
effects and thus, among patients with unsatisfactory thera-
peutic response to compounds with peripheral action, cen-
trally acting antagonists may be needed. Based on our
existing knowledge concerning the role of genetic, pheno-
typic and environmental factors the selection of persons
who are at no or low risk for psychiatric adverse effects
may be possible. Molecular mechanisms and receptors
involved in the effects of stress and anxiety-related neuro-
circuitries sensitive to CB1 receptor antagonists, like the
serotonergic and noradrenergic systems which regulate
the synthesis of the endocannabinoid 2-arachydonoyl-
glycerol mediated by 5-HT2C and a1 receptors can be
identified [1]. Furthermore, variants of the serotonin trans-
porter and the CB1 receptor genes have been shown to
modulate stress-induced anxiety in human studies [1].
In conclusion, development of peripherally acting, or the
use of personalised medicine for centrally acting CB1
receptor antagonists are promising approaches with
diverse advantages.
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